INTRODUCTION {#S1}
============

Liver cancer has the most rapidly growing mortality rate in the U.S., relative to other cancers, and it is the 3^rd^ cause of death by cancer worldwide^[@R32]^. Investigations of genes involved in liver cancer have focused on Sal-like protein 4 (*SALL4*), a marker of embryonic stem cells^[@R41]^ and a prognostic marker in liver cancer^[@R14],\ [@R27],\ [@R37]^. SALL4 is an oncofetal protein expressed at high levels in fetal liver while its expression is silenced in adult hepatocytes^[@R26]^. Recent studies have shown increased expression of SALL4 in poor survival HCCs^[@R14]^. SALL4 is re-expressed in 95 of 171 HBV-related HCC patients (55.6%) with unfavorable prognosis^[@R37]^. SALL4 expression exhibits a strong positive correlation with expression of EpCAM, hepatic stem cell markers, and AFP^[@R29],\ [@R36],\ [@R38]^. Importantly, SALL4 expression enhanced formation of spheroids and invasion capacities of HCC-derived cell lines, while SALL4 knockdown led to reduction in expression of these markers, and attenuation of invasion capacity^[@R38]^. These findings support a role for SALL4 in hepatocarcinogenesis associated with unfavorable prognosis. Accordingly, SALL4 has been proposed as a novel therapeutic target for liver cancer, although transcription factors are not effective druggable targets^[@R23],\ [@R27]^.

Given the important role of SALL4 in liver cancer, we aimed to investigate the molecular mechanism that enables re-expression of the *SALL4* gene in liver tumors. The *SALL4* promoter contains high affinity signal transducer and activator of transcription 3 (STAT3) binding sites, and down-regulation of STAT3 significantly reduced SALL4 expression^[@R3]^. In embryonic stem cells (ESCs) SALL4 expression was dramatically enhanced by overexpression of octamer-binding transcription factor 4 (OCT4)^[@R34]^. Furthermore, in ESCs the BRG1/Brahma-associated factors (BAFs) complex occupies the *SALL4* promoter, suggesting the BAF complex may also have a regulatory role in SALL4 re-expression in tumors^[@R11]^. Significantly, the activity and expression of SALL4 is epigenetically regulated. For example, the histone deacetylase inhibitor successfully suppressed proliferation of SALL4-positive hepatocellular carcinoma cells, while the DNA methylation inhibitor 5-azacytidine (5AZA) specifically reversed repressive effect of SALL4 on its own expression as well as on SALL4 target genes^[@R35]^. SALL4 level was reduced by overexpression of miR-107, and the inverse was observed when miR-107 was knocked-down^[@R9]^. In addition, H3K27 demethylase Utx directly regulates re-expression of *SALL4* in somatic and germ cell reprogramming^[@R22]^ while DNA (cytosine-5)-methyltransferase 3-like (DNMT3L) is required to suppress SALL4 splicing variant SALL4B^[@R19]^. Genome-wide DNA methylation analysis in ESCs revealed *SALL4* was hypo-methylated in stem cell-specific differentially methylated regions (SS-DMRs)^[@R25]^.

However, little is known about the molecular mechanism regulating re-expression of *SALL4* in liver tumors. Since *SALL4* is re-expressed in nearly 50% of HBV-related HCCs^[@R37]^, in this study we investigated how HBV infection regulates *SALL4* expression, employing *in vitro* HBV replication^[@R17]^ and infection models^[@R24]^. Herein, we identify a cluster of CpG sites that become demethylated in HBV replicating cells and HBV-related liver tumors. These CpG sites, located downstream from the TSS of *SALL4*, upon DNA demethylation enable STAT3 and OCT4 binding, recruitment of chromatin remodeling complex containing BRG1, and increased RNA Polymerase II association with *SALL4* chromatin, resulting in enhanced *SALL4* transcription. Furthermore, we provide evidence that this mechanism of SALL4 re-expression is also functional in HCC of other etiologies, including HCV-related HCCs, and in human liver cancer cell lines expressing elevated SALL4 mRNA^[@R37]^.

RESULTS {#S2}
=======

DNA demethylation of specific CpG sites located downstream of SALL4 TSS in HBV-related HCCs {#S3}
-------------------------------------------------------------------------------------------

Our studies demonstrated hepatitis B virus X protein induces EpCAM expression via active DNA demethylation^[@R7]^. To examine whether *SALL4* transcription is also regulated by HBV via a similar DNA demethylation mechanism, we performed sodium bisulfate sequencing PCR of DNA isolated from HBV-related HCCs (T) and paired peritumor liver tissue (PT). Firstly, we quantified SALL4 expression employing seventeen clinical samples. Of them, five patients showed slightly elevated mRNA level (left panel, [Fig. 1a](#F1){ref-type="fig"}) and four patients showed significantly increased SALL4 mRNA levels (right panel, [Fig. 1a](#F1){ref-type="fig"}), compared to PT tissue. SALL4 mRNA expression was either not upregulated or reduced in the remaining eight patients ([Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}).

Transcription factor binding sites (TFBS) are usually located 1--2 kb upstream of the transcription start site (TSS)^[@R4]^. Accordingly, we used the 5' flanking sequence of *SALL4* spanning 2Kb upstream and 500 bp downstream from TSS for CpG island and TFBS prediction ([Fig. 1b](#F1){ref-type="fig"}). Sequence analysis revealed 34 CpG sites and multiple TFBS, including STAT3 and OCT4 binding sites, located downstream from the *SALL4* TSS ([Fig. 1b](#F1){ref-type="fig"}).

Next, we used samples from patients \#24 and \#72, exhibiting high expression of SALL4 mRNA, 209-fold and 71-fold respectively, and patient \#75 with small 2.6-fold induction of SALL4 mRNA ([Fig. 1a](#F1){ref-type="fig"}). Sodium bisulfite sequencing PCR demonstrated vast DNA demethylation in T sample \#24 ([Fig. 1c](#F1){ref-type="fig"}) and \#72 ([Fig. 1d](#F1){ref-type="fig"}). Interestingly, these T samples exhibited high expression of SALL4 mRNA ([Fig. 1a](#F1){ref-type="fig"}). By contrast, comparison of DNA methylation pattern between T *vs*. PT tissue from patient \#75, exhibiting moderate SALL4 mRNA expression ([Fig. 1a](#F1){ref-type="fig"}), showed that CpG sites 12--13 and 24--27 were demethylated in the tumor, suggesting that demethylation at those sites is functionally important for *SALL4* re-expression ([Fig. 1e](#F1){ref-type="fig"}).

HBV infection induces DNA demethylation of specific SALL4 CpG sites {#S4}
-------------------------------------------------------------------

Since the observed DNA demethylation of CpG sites located downstream from *SALL4* TSS in HBV-related HCCs occurs in the context of chronic HBV infection, we investigated whether this *SALL4* CpG site demethylation also occurs upon HBV infection of hepatocytes *in vitro*. We employed the recently developed HBV infection model of the HepG2^hNTCP^ cell line^[@R24]^. HepG2^hNTCP^ cells express sodium taurocholate co-transporting peptide (NTCP) that specifically binds HBV preS1 protein and can be directly infected by purified HBV virus. Quantification of viral HBeAg and pregenomic RNA were used to detect HBV infection in HepG2^hNTCP^ cells ([Fig. 2a](#F2){ref-type="fig"}). Indeed, HBV-infected HepG2^hNTCP^ cells showed increased expression of SALL4 splicing variants SALL4A and SALL4B ([Fig. 2b](#F2){ref-type="fig"}). Interestingly, sodium bisulfite sequencing analyses of DNA isolated from cells infected with HBV for 4 days and 6 days displayed a progressive increase in DNA demethylation of specific CpG sites located downstream of *SALL4* TSS ([Fig. 2c](#F2){ref-type="fig"}). Statistical analysis by QUMA^[@R16]^ displayed significant hypomethylation at CpG sites 12--14 and 24--26 ([Supplementary Fig. 2a](#SD3){ref-type="supplementary-material"}). These CpG sites were also found hypomethylated in HBV-related HCCs ([Fig. 1](#F1){ref-type="fig"}) and interestingly, they are located within or adjacent to putative binding sites for OCT4 and STAT3 ([Fig. 2c](#F2){ref-type="fig"}).

To further verify these DNA demethylation results derived from clinical samples and the HepG2^hNTCP^ HBV infection model, we also employed the HepAD38 cell line, a cellular model for HBV replication^[@R17]^. HepAD38 cells, derived from the HepG2 human liver cancer cell line, contain an integrated copy of the HBV genome under control of the Tet-off promoter, and HBV replication is initiated by tetracycline removal^[@R17]^. Under conditions of HBV replication by tetracycline removal for 5 days (D5), 10 days (D10) and 20 days (D20), monitored by increased protein levels of viral HBc antigen ([Fig. 3b](#F3){ref-type="fig"}), qRT-PCR results showed significant mRNA induction of SALL4A and SALL4B splicing variants at D10 and D20 ([Fig. 3a](#F3){ref-type="fig"}). Protein expression results by immunoblotting confirmed this mRNA increase ([Fig. 3b](#F3){ref-type="fig"}). Interestingly, significant DNA demethylation was observed at D10 and D20 of HBV replication but not on D5, compared to cells without HBV replication ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 3a and b](#SD4){ref-type="supplementary-material"}). Importantly, in D10 and D20 of HBV replicating HepAD38 cells, CpG sites 12--14 and 24--27 were hypomethylated, agreeing with results derived from HBV infected HepG2^hNTCP^ ([Fig. 2](#F2){ref-type="fig"}) and HBV-related HCCs ([Fig. 1](#F1){ref-type="fig"}). Thus, we interpret these results to indicate that DNA demethylation of CpG sites 12--14 and 24--27 downstream of the TSS is functionally important in *SALL4* re-expression.

To link SALL4 mRNA expression to DNA demethylation, we treated HepAD38 cells with 5AZA, an inhibitor of DNA methyltransferases (DNMTs). Indeed, SALL4 mRNA levels were elevated by treatment with 5AZA in the absence of HBV replication ([Fig. 3d](#F3){ref-type="fig"}). These results indicate that DNA demethylation is required for SALL4 re-expression in hepatocytes, involving a passive mechanism.

SALL4 re-expression in liver cancer cell lines and HCV-related HCCs via DNA demethylation {#S5}
-----------------------------------------------------------------------------------------

To further confirm this mechanism of *SALL4* re-expression observed in differentiated hepatocytes, we developed a methylation specific PCR (MSP) assay^[@R10]^. The MSP assay involves modification of DNA by sodium bisulfite to convert unmethylated cytosines to uracil, followed by PCR amplification with primers specific for the methylated DNA^[@R10]^. Specifically, employing the HepAD38 cell line as our positive control, which exhibits HBV replication-dependent DNA demethylation ([Fig. 3](#F3){ref-type="fig"}), we designed primers to detect the methylation state of CpG sites associated with OCT4 and STAT3 binding sites at positions CpG13 and CpG24--26, downstream from *SALL4* TSS. In agreement with the HepAD38 bisulfite sequencing data ([Fig. 3c](#F3){ref-type="fig"}) our MSP primers exhibited reduced methylation of CpG13 and CpG24--26 sites, employing genomic DNA isolated from HepAD38 cells on D10 of HBV replication ([Fig. 4a](#F4){ref-type="fig"}).

To further validate the MSP assay, we analyzed human liver cancer cell lines shown in earlier studies^[@R37]^ to re-express *SALL4*. Indeed, in comparison to HepAD38 cells not replicating the virus, *SALL4* is highly re-expressed in Huh7 and Hep3B cell lines ([Fig. 4b](#F4){ref-type="fig"}), in agreement with earlier studies by others^[@R37]^. Employing genomic DNA from these cell lines, including genomic DNA from HepAD38 cells without HBV replication, we demonstrate that indeed the designed PCR primers distinguish methylated vs. unmethylated DNA at those CpG sites ([Fig. 4c](#F4){ref-type="fig"}). More importantly, the results demonstrate that HCC cell lines that re-express SALL4 also exhibit demethylation of these CpG sites downstream of the *SALL4* TSS, suggesting that this mechanism is operational in liver cancer independent of HBV infection ([Fig. 4c](#F4){ref-type="fig"}).

Next, we examined SALL4 expression in T vs. PT tissue from a small cohort of chronic HBV infected patients with HCC, and another cohort of HCV-associated HCCs. Three out of five HBV-related HCCs and 11 out of 18 HCV-related HCCs were positive for SALL4 expression ([Fig. 4d and Fig. 4f](#F4){ref-type="fig"}). Indeed, our MSP analyses demonstrate that the state of DNA methylation at the *SALL4* regulatory region differed between T and PT tissue in *SALL4* expressing tumors ([Fig. 4e and h](#F4){ref-type="fig"}). HCV-related HCCs expressing *SALL4* exhibited a statistically significant reduction (p\<0.05) in DNA methylation at CpG positions 13 and 24--26 ([Fig. 4g](#F4){ref-type="fig"}). Importantly, HCCs expressing *SALL4* exhibit demethylation of at least one of the CpG sites associated with OCT4 or STAT3 binding sites ([Fig. 4e and h](#F4){ref-type="fig"}). We conclude, DNA demethylation of CpG sites associated with OCT4 and/or STAT3 binding sites located downstream from the *SALL4* TSS, is functionally relevant for re-expression of SALL4 in hepatocarcinogenesis.

CpG site methylation downstream of SALL4 TSS interferes with RNA polymerase II elongation {#S6}
-----------------------------------------------------------------------------------------

Since DNA methylation at coding region boundaries^[@R6]^ negatively influences RNA polymerase II binding to chromatin^[@R20]^ and elongation rate^[@R33]^, we performed ChIP assays to quantify RNA polymerase II occupancy in *SALL4* regulatory region located in boundary region of exon 1, using primer set 1 ([Fig. 5a](#F5){ref-type="fig"}). In addition, in order to monitor association of RNA polymerase II with chromatin of exons 2--4, as a function of HBV replication, we used primer sets 2--4 ([Fig. 5a](#F5){ref-type="fig"}). Increased association (50%) of RNA polymerase II was detected by ChIP assays with exon 1 on D0, i.e., without HBV replication, in comparison to exons 2--4 ([Fig. 5a](#F5){ref-type="fig"}). Similarly, at D5 of HBV replication, when CpG sites in boundary of exon 1 were still methylated ([Fig. 3c](#F3){ref-type="fig"}), RNA polymerase II associated primarily with exon 1([Fig. 5a](#F5){ref-type="fig"}). By contrast, at D10 of HBV replication, ChIP assays demonstrated increased association of RNA polymerase II with the chromatin of all *SALL4* gene exons ([Fig. 5a](#F5){ref-type="fig"}). RNA immunoprecipitation (RIP) assays employing RNA polymerase II antibody confirmed that RNA polymerase II associated with significantly increased SALL4 transcript at D10 of HBV replication, corresponding to both exon1 and exon 4 ([Fig. 5b](#F5){ref-type="fig"}). By contrast, in the absence of HBV replication (D0), RIP assays show that RNA Polymerase II was primarily in association with RNA corresponding to exon 1. Taken together, we interpret these result to mean that in the absence of HBV replication (D0), or when CpG sites located in the boundary of exon 1 were methylated, as on D5 of HBV replication ([Fig. 5a](#F5){ref-type="fig"}), RNA polymerase II was paused at the region of the methylated CpG sites. Upon demethylation of these CpG sites RNA polymerase II resumed transcription elongation.

HBV replication-induced DNA demethylation facilitates binding and interaction of STAT3, OCT4 and BRG1 {#S7}
-----------------------------------------------------------------------------------------------------

Interestingly, the CpG sites that were demethylated both in HBV-related HCCs and in HBV infected and replicating cells are located within or adjacent to putative transcription factor binding sites. CpG sites 13 and 14 are located in an OCT4 binding site, and CpG sites 23--26 in a STAT3 binding site. Earlier studies demonstrated that STAT3^[@R3]^ and OCT4^[@R34]^ bind to their cis-acting sequences located in *SALL4* promoter region and activate *SALL4* expression in ESCs. Interestingly, our results suggest that DNA methylation of STAT3 and OCT4 sites located downstream of the *SALL4* TSS, prevent SALL4 transcription in differentiated hepatocytes. To directly demonstrate whether DNA demethylation affects binding of OCT4 and STAT3 at their respective binding sites downstream from the TSS, we carried out ChIP assays, using OCT4 and STAT3 antibodies. ChIP results show increased binding of STAT3 and OCT4 ([Fig. 6a](#F6){ref-type="fig"}) at those sites in the presence of HBV replication at D10, i.e. when the CpG sites become demethylated ([Fig. 3c](#F3){ref-type="fig"}).

In ESCs the chromatin remodeling BRG1/BAF complex occupies the *SALL4* promoter^[@R11]^. Accordingly, we examined whether BRG1 has a role in *SALL4* re-expression in HBV infected, differentiated hepatocytes. Accordingly, we performed ChIP assays with BRG1 antibody, representing BAF complex, as a function of HBV replication. Interestingly, BRG1 exhibited increased occupancy of the same *SALL4* regulatory region downstream of the TSS that also associated with OCT4 and STAT3, on D10 of HBV replication ([Fig. 6a](#F6){ref-type="fig"}). Reciprocal co-immunoprecipitations using lysates from HepAD38 cells demonstrated that BRG1 interacts with both OCT4 and STAT3, irrespective of HBV replication ([Fig. 6b](#F6){ref-type="fig"}).

To examine whether STAT3, OCT4 and BRG1 are involved in regulation of *SALL4* transcription following DNA demethylation of CpG sites downstream of *SALL4* TSS, we performed sequential ChIP assays as a function of HBV replication ([Fig. 6c](#F6){ref-type="fig"}). ChIP assays with BRG1 antibody, followed by tandem immunoprecipitation with OCT4 or STAT3 antibody showed enhanced co-occupancy of the *SALL4* regulatory region downstream from the TSS, on D10 of HBV replication. These results support that following CpG site demethylation of the *SALL4* regulatory region downstream from TSS, OCT4 and STAT3 bind to the respective demethylated binding sites and assemble a complex with BRG1, enabling remodeling of chromatin and *SALL4* transcription.

To test this hypothesis, we investigated the functional role of BRG1 in *SALL4* transcription. We knocked-down BRG1 on D8 of HBV replication in HepAD38 cells. Indeed, BRG1 knockdown reduced mRNA and protein level of both splicing forms of SALL4, SALL4A and SALLB ([Fig. 7a](#F7){ref-type="fig"}). Conversely, BRG1 overexpression enhanced expression of both SALL4 splicing variants ([Fig. 7b](#F7){ref-type="fig"}). A diagram depicting our working model is shown in [Fig. 7c](#F7){ref-type="fig"}.

A positive correlation between SALL4 expression and hepatic cancer stem cell (hCSC) markers in HBV-induced HCCs {#S8}
---------------------------------------------------------------------------------------------------------------

A recent study demonstrated that in mouse embryonic fibroblasts (MEFs), ectopic expression of Sall4, Nanog, Esrrb, and Lin28 (SNEL) generated induced pluripotent stem cells (iPSCs) more efficiently than other factor combinations, including OSKM (Oct4, Sox2, Klf4, and Myc)^[@R5]^. Considering the clinical significance of SALL4 in liver cancer^[@R27],\ [@R37],\ [@R38]^, and the potential role of SALL4 in prognosis and therapeutics^[@R23]^, we analyzed correlation of *SALL4* expression in HBV-related HCCs with expression of *NANOG*, one of the SNEL factors, and of hepatic cancer stem cell marker *EpCAM* ([Fig. 8](#F8){ref-type="fig"}). Indeed, a statistically significant correlation was quantified between *SALL4* and *EpCAM* expression in HBV-related HCCs ([Fig. 8a](#F8){ref-type="fig"}), as reported earlier for HCCs. More importantly, a statistically significant correlation also exists between *SALL4* and *NANOG* expression ([Fig. 8b](#F8){ref-type="fig"}), supporting a link of SALL4 to pluripotency. Lastly, sequence analysis shows that the CpG island and OCT4 binding site downstream of *SALL4* TSS is conserved across species ([Fig. 8c](#F8){ref-type="fig"}), supporting the essential function of these elements in SALL4 expression.

DISCUSSION {#S9}
==========

It is widely accepted that hepatocarcinogenesis is a long-term process associated with accumulation of genetic and epigenetic alterations, resulting in activation of oncogenes and/or loss of tumor suppressors^[@R2]^. Recent studies have shown deregulated expression of *SALL4* in HCC^[@R27],\ [@R37],\ [@R38]^ and association with poor prognosis^[@R37],\ [@R38]^. Although *SALL4* transcriptional regulation has been studied in the context of ESCs^[@R34]^, how *SALL4* re-expression occurs during hepatocarcinogenesis is not well understood.

In this study, we demonstrate that HBV-related HCCs, characterized by elevated SALL4 expression, display pronounced hypomethylation of the *SALL4* regulatory region downstream from the TSS ([Figs. 1](#F1){ref-type="fig"} and [4](#F4){ref-type="fig"}). Importantly, the amount of DNA methylation at the *SALL4* regulatory region differed between T and PT tissue ([Figs. 1](#F1){ref-type="fig"} and [4](#F4){ref-type="fig"}), suggesting changes in DNA methylation of this regulatory region influence levels of *SALL4* transcription. We also observed DNA demethylation of this *SALL4* regulatory region in the context of HBV infection and replication *in vitro* ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Furthermore, employing a methylation-specific assay^[@R10]^ we observed DNA demethylation of these CpG sites in HBV- and HCV-related HCCs, as well as in liver cancer cell lines^[@R37]^ that overexpress SALL4 ([Fig. 4](#F4){ref-type="fig"}). Since there is no report about DNA methylation regulating *SALL4* expression in tumors, we retrieved array-based DNA methylation platform data (Illumina HumanMethylation450K BeadChip) from TCGA (The Cancer Genome Atlas, <http://cancergenome.nih.gov/>) (data not shown). Nineteen probes are available for the genomic region of *SALL4*, five of which are located in CpG islands. However, all of these CpG sites reside in the gene body of *SALL4* and exhibit no DNA methylation differences between T *vs*. PT tissue. Since DNA methylation in the vicinity of the TSS *vs*. the gene body^[@R13]^ exerts different effects on transcription, we examined DNA methylation of a CpG island located downstream of the *SALL4* TSS ([Fig. 1](#F1){ref-type="fig"}).

Importantly, our findings link hypomethylation of CpG sites in *SALL4* regulatory region to enhanced *SALL4* transcription. In HBV replicating cells, we quantified increased association of RNA polymerase II with *SALL4* chromatin and SALL4 mRNA, employing RNA polymerase II ChIP and RIP assays, respectively ([Fig. 5a and b](#F5){ref-type="fig"}). Our studies also suggest that DNA methylation at CpG sites downstream of the *SALL4* TSS result in RNA polymerase II pausing ([Fig. 5a](#F5){ref-type="fig"}). Pausing of RNA polymerase II during early elongation is a widespread regulatory mechanism^[@R1]^. However, further studies are needed to determine whether and how DNA demethylation of specific CpG sites directly regulates RNA polymerase II pausing and *SALL4* transcription.

We also show that the mechanism of enhanced *SALL4* transcription due to hypomethylation of specific CpG sites involves transcription factors OCT4 and STAT3. In HBV replicating cells, ChIP assays revealed enhanced STAT3 and OCT4 binding to hypomethylated sites located downstream of the *SALL4* TSS ([Fig. 6](#F6){ref-type="fig"}). Since STAT3 and OCT4 interact with embryonic stem cell BAF (esBAF) complex and activate transcription of their target genes^[@R12]^, we reasoned that STAT3 and OCT4 may interact with BAF complex in *SALL4* regulatory region. Indeed, our co-immunoprecipitation results and more importantly our sequential/tandem ChIP assays with BRG1 and STAT3 or OCT4 antibodies support this hypothesis ([Fig. 6c](#F6){ref-type="fig"}). Consistent with previous genome-wide promoter analysis of BRG1 occupancy of the *SALL4* regulatory region in ESCs^[@R15]^, our results show that BRG1 recruitment by STAT3 and OCT4 binding at sites downstream of the *SALL4* TSS enable its re-expression in HBV replicating, differentiated hepatocytes ([Fig. 7a and b](#F7){ref-type="fig"}).

OCT4, along with NANOG and SOX2, is expressed exclusively in ESCs^[@R28]^ and is a target of repression by the chromatin modifying polycomb repressive complex 2 (PRC2)^[@R30]^. Our recent studies have identified a molecular mechanism that leads to loss of PRC2 function initiated by the HBV X protein^[@R39]^. Moreover, our new findings show that in the context of loss of PRC2 function, in a subpopulation of HBV replicating cells, there is enhanced expression of pluripotency transcription factors OCT4, NANOG and SOX2^[@R21],\ [@R40]^, thus identifying cell intrinsic changes occurring in HBV replicating cells that likely contribute to *SALL4* re-expression. Indeed, we demonstrate that a positive correlation exists between SALL4, EpCAM and NANOG in HBV-related HCCs, as observed by others^[@R29],\ [@R38]^, and that the OCT4 binding site and its associated CpG sites are evolutionarily conserved ([Fig. 8](#F8){ref-type="fig"}). Whether the same cell intrinsic changes involving PRC2 downregulation occur in HCCs of other etiologies, e.g., HCV-associated HCCs, enabling SALL4 expression remain to be determined.

MATERIALS AND METHODS {#S10}
=====================

Tissue samples and cell lines {#S11}
-----------------------------

Paired liver tissues from chronic HBV and HCV patients with HCC, tumor and peritumor were obtained from the French National Biological Resources Center following approved consent from the French Liver Tumor Network Scientific Committee. The HepG2^hNTCP\ [@R24]^ and HepAD38^[@R17]^ cell lines that support HBV infection and replication, respectively, were grown as described. Secreted hepatitis B e antigen (HBeAg) was measured by HBeAg ELISA kit (AUTOBIO DIAGNOSTICS CO., Zhengzhou, China). Treatment of indicated cell lines with 10µM 5-Aza-2'-Deoxycytidine (Cayman Chemical, Ann Arbor, MI) was for 48h.

Sodium bisulfite sequencing PCR (BSP) {#S12}
-------------------------------------

BSP was performed as previously described^[@R7]^. Human SALL4 CpG island was predicted and bisulfIte sequencing primers were designed by Methprimer^[@R18]^ and listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Primers for methylation specific PCR are listed in [supplementary Table 1](#SD1){ref-type="supplementary-material"}. Equal amount of genomic DNA was amplified under identical amplification conditions.

Chromatin immunoprecipitation (ChIP) assays, immunoprecipitations and immunoblotting {#S13}
------------------------------------------------------------------------------------

These analyses were carried out as previously described^[@R7]^. The following antibodies were used in this study: SALL4 antibody (Abcam, Cambridge, MA); HBc antibody (Dako, Carpinteria, CA); RNA polymerase II antibody (Santa cruz biotechnology, Dallas, Texas); BRG1 antibody (Abcam, Cambridge, MA); STAT3 antibody (Santa Cruz biotechnology, Dallas, Texas); OCT4 antibody (Abcam, Cambridge, MA); H3K27me3 antibody (Abcam, Cambridge, MA); Histone 3 antibody (Active Motif, Carlsbad, CA). ChIP primer sequences listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

RNA immunoprecipitation (RIP) {#S14}
-----------------------------

We followed the standard protocol described previously^[@R31]^. RNA polymerase II antibody (Santa Cruz biotechnology, Dallas, Texas) was used for IP and iScript cDNA Synthesis Kit (Bio-Rad, Hercules, California) was employed for reverse transcription of RNA. RIP primer sequences are available in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Transient transfections {#S15}
-----------------------

Transient transfections in HepAD38 cells were performed employing Lipofectamine 2000 (Invitrogen, Grand Island, NY) as described by manufacturer with 10µg of BRG1 mammalian expression plasmid^[@R8]^ (Addgene, Cambridge, MA). BRG1 siRNA and scrambled control siRNA (Invitrogen, Grand Island, NY) were transfected using Lipofectamine RNAi MAX (Invitrogen, Grand Island, NY).

Reverse transcription and quantitative real-time PCR (QPCR) {#S16}
-----------------------------------------------------------

RNA isolation, reverse transcription and real-time PCR were performed and analyzed as described^[@R7]^. PCR primer sequences are listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Statistical analyses {#S17}
--------------------

Statistical significance was assessed by Student's t-test. Data were expressed as mean ± standard deviation (SD) and \**P*\< 0.05 and \*\**P*\< 0.01 were considered significant.
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![*SALL4* expression is associated with DNA demethylation in a subgroup of HBV-related HCCs\
(**a**) PCR quantification of SALL4 mRNA in HBV-related HCCs with mild (Left panel) and extreme increase (Right panel) of SALL4 expression. PT, peritumor; T, tumor. (**b**) Mapping of CpG dinucleotides in human *SALL4* gene. The transcriptional start site (TSS), numbered CpG sites, OCT4 and STAT3 binding sites, and the position of bisulfite sequencing primers are indicated. (**c--e**) Bisulfite sequencing PCR of SALL4 clones, using DNA from patients \#24 (**c**), \#72 (**d**), and \#75 (**e**), as indicated in Fig. 1a. Open and closed circles denote unmethylated and methylated states, respectively.](nihms818021f1){#F1}

![HBV infection induces DNA demethylation of *SALL4* in HepG2^hNTCP^ cell line\
(**a**) Quantification of secreted HBeAg by ELISA (Left panel), and quantification of pregenomic RNA by QPCR (Right panel) after HBV infection for 6 days. (**b**) Quantification of *SALL4* gene expression (SALL4A and SALL4B slicing variants) by QPCR after HBV infection for 4 and 6 days (D4, D6). (**c**) Bisulfite sequencing PCR results of *SALL4* clones, using DNA from HepG2^hNTCP^ cells without (−) HBV infection (D0) or with (+) HBV infection at 4 and 6 days (D4 and D6). Open and closed circles denote unmethylated and methylated states, respectively. Error bars denote S.D. \**P*\< 0.05; \*\**P*\< 0.01.](nihms818021f2){#F2}

![HBV replication induces DNA demethylation of *SALL4* in HepAD38 cell line\
(**a**) PCR quantification of SALL4 mRNA in HepAD38 cells grown without (−) HBV replication (D0) or with (+) HBV replication by tetracycline removal for 5, 10, 20 days (D5--D20). Results are from three independent RNA isolations performed in identical triplicates. Error bars denote S.D. \**P*\< 0.05; \*\**P*\< 0.01. (**b**) Immunoblot of SALL4 protein in HepAD38 cells −/+ HBV replication by tetracycline removal for D0--D20. (**c**) Bisulfite sequencing PCR results of SALL4 clones, using DNA from HepAD38 cells −/+ HBV replication by tetracycline removal for D0--D10. Open and closed circles denote unmethylated and methylated states, respectively. (**d**) QPCR of SALL4 mRNA following treatment with 10 µM 5-Aza-2-deoxycytidine (5AZA) or DMSO (vehicle control) for 48hr. Results are from three independent RNA isolations performed in identical triplicates. Error bars denote S.D. \**P*\< 0.05; \*\**P*\< 0.01.](nihms818021f3){#F3}

![SALL4 re-expression in liver cancer cell lines and HCV-related HCCs via DNA demethylation\
(**a**) Methylation-specific PCR (MSP) assay for *SALL4* CpG site 13 and CpG sites 24--26, employing genomic DNA from HepAD38 cells grown without (−) and with (+) HBV replication for 10 days, analyzed 2% agarose gel electrophoresis. Relative intensity quantified by ImageJ software is ratio of +/− HBV replication. (**b**) QRT-PCR of SALL4 mRNA expression employing RNA from HepAD38 cells grown in the absence of HBV replication, Huh7 and Hep3B cell lines. Data normalized to GAPDH. −ΔCt values are shown. (**c**) MSP assay for CpG site 13 and CpG24--26 using genomic DNA from HepAD38 (without HBV replication), Huh7 and Hep3B cells, analyzed by 2% agarose gel electrophoresis. Relative intensity quantified by ImageJ software is ratio of signal from Huh7 or Hep3B to HepAD38 cells. (**d**) and (**f**) QRT-PCR of SALL4 mRNA expression in HBV- and HCV- related liver tumors (T) *vs.* peritumoral tissue (PT); (**e**) and (**h**) MSP assay for methylation of CpG13 and CpG24--26 sites using genomic DNA of HBV- and HCV- related HCCs; relative intensity is ratio of T/PT. (**g**) Statistical analysis for methylation status of *SALL4* CpG13 and CpG24--26 sites in patient samples with SALL4^High^ and SALL4^low^ mRNA expression, using unpaired t test; *P* \< 0.05.](nihms818021f4){#F4}

![DNA methylation downstream of SALL4 TSS interferes with RNA polymerase II elongation\
(**a**) Diagram of SALL4 gene. TSS and exon1--4 are shown. ChIP assays with RNA polymerase II antibody, employing HepAD38 cells grown −/+ HBV replication by tetracycline removal for D0--D10, and SALL4 primers spanning different exons, as indicated. (**b**) RIP assays with RNA polymerase II antibody, employing HepAD38 cells grown −/+ HBV replication by tetracycline removal for D0 and D10, and SALL4 primers spanning exons 1 and 4, as indicated in (a).](nihms818021f5){#F5}

![HBV replication enables binding and interaction of STAT3, OCT4 and BRG1 in *SALL4* regulatory region\
(**a**) ChIP assays with STAT3, OCT4, and BRG1 antibodies, as indicated, employing HepAD38 cells grown −/+ HBV replication by tetracycline removal for D0 and D10, and SALL4 primers spanning CpG sites shown in [Fig.1b](#F1){ref-type="fig"}. Data were quantified as % of input. (**b**) Co-immunoprecipitations (co-IPs) of STAT3, OCT4 and BRG1 using indicated antibodies, employing extracts from HepAD38 cells grown −/+ HBV replication by tetracycline removal for D0 and D10. A representative assay is shown from three independent experiments. (**c**) Sequential ChIP assays of HepAD38 cells −/+ HBV replication by tetracycline removal for D0 and D10, using BRG1 antibody followed by tandem IP with STAT3 or OCT4 antibody. Results are from three independent experiments. Data were quantified as % of input.](nihms818021f6){#F6}

![BRG1/BAF complex is involved in *SALL4* re-expression in HBV replicating hepatocytes\
(**a, b**) PCR quantification of SALL4 mRNA (Left panel), and immunoblots of SALL4 (Right panel), following transfection of BRG1 siRNA (siBRG1) (**a**), and BRG1 plasmid (**b**), in HepAD38 cells grown with HBV replication by tetracycline removal for 10 days. Results are from three independent RNA isolations performed in identical triplicates. Error bars represent S.D. \**P*\< 0.05 and \*\**P*\< 0.01. BRG1 knockdown and BGR1 overexpression (OE) were confirmed by PCR and immunoblots. (**c**) A proposed schematic model depicting epigenetic mechanism by which *SALL4* is re-expressed during HBV replication.](nihms818021f7){#F7}

![*SALL4* expression correlates with expression of *EpCAM* and *NANOG* in HBV-related HCCs\
Scatter plot analysis of SALL4 mRNA expression positively correlated with those of (**a**) EpCAM and (**b**) NANOG mRNAs expressed in HBV-related HCCs, quantified by Spearman's correlation coefficient (r). (**c**) Sequence analysis of the regulatory region downstream of *SALL4* TSS across species. The conserved sequences, CpG sites and OCT4 binding site are shown.](nihms818021f8){#F8}
